Hydrocortisone plus fludrocortisone for adults with septic shock.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Septic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock. METHODS: In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included mortality at intensive care unit (ICU) discharge and hospital discharge and at day 28 and day 180 and the number of days alive and free of vasopressors, mechanical ventilation, or organ failure. After drotrecogin alfa (activated) was withdrawn from the market, the trial continued with a two-group parallel design. The analysis compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo group). RESULTS: Among the 1241 patients included in the trial, the 90-day mortality was 43.0% (264 of 614 patients) in the hydrocortisone-plus-fludrocortisone group and 49.1% (308 of 627 patients) in the placebo group (P=0.03). The relative risk of death in the hydrocortisone-plus-fludrocortisone group was 0.88 (95% confidence interval, 0.78 to 0.99). Mortality was significantly lower in the hydrocortisone-plus-fludrocortisone group than in the placebo group at ICU discharge (35.4% vs. 41.0%, P=0.04), hospital discharge (39.0% vs. 45.3%, P=0.02), and day 180 (46.6% vs. 52.5%, P=0.04) but not at day 28 (33.7% and 38.9%, respectively; P=0.06). The number of vasopressor-free days to day 28 was significantly higher in the hydrocortisone-plus-fludrocortisone group than in the placebo group (17 vs. 15 days, P<0.001), as was the number of organ-failure-free days (14 vs. 12 days, P=0.003). The number of ventilator-free days was similar in the two groups (11 days in the hydrocortisone-plus-fludrocortisone group and 10 in the placebo group, P=0.07). The rate of serious adverse events did not differ significantly between the two groups, but hyperglycemia was more common in hydrocortisone-plus-fludrocortisone group. CONCLUSIONS: In this trial involving patients with septic shock, 90-day all-cause mortality was lower among those who received hydrocortisone plus fludrocortisone than among those who received placebo. (Funded by Programme Hospitalier de Recherche Clinique 2007 of the French Ministry of Social Affairs and Health; APROCCHSS ClinicalTrials.gov number, NCT00625209 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“In APROCCHSS [478] the dose of vasopressor was ≥ 0.25 µg/kg/min or ≥ 1 mg/h of norepinephrine or epinephrine, or any other vasopressor for at least 6 h to maintain a MAP ≥ 65 mmHg.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationDellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationVincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Self-citationShankar-Hari, M., Phillips, G. S., Levy, M. L., Seymour, C. W., Liu, V. X., Deutschman, C. S., Angus, D. C., Rubenfeld, G. D., Singer, M., & for the Sepsis Definitions Task Force (2016) · JAMA · doi:10.1001/jama.2016.0289 · Cited by 2,424
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Self-citationAnnane, D., Bellissant, E., & Cavaillon, J.-M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17667-8 · Cited by 1,213
Self-citationAnnane, D., Vignon, P., Renault, A., Bollaert, P.-E., Charpentier, C., Martin, C., Troché, G., Ricard, J.-D., Nitenberg, G., Papazian, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61344-0 · Cited by 567
Self-citationCognitive decline after sepsis.
Annane, D., & Sharshar, T. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70246-2 · Cited by 290
Self-citation
Research works printed but not linked: 1
- Guide “100 recommandations pour la surveillance et la préventions des infections nosocomiales.” Bulletin Epidémiologique Hebdomadaire. No. 48. November 30 1992 (http://invs.santepubliquefrance.fr/beh/1992/48/index.html).
Cited by
Items 601–700 of 968
Vasopressor Therapy in the Intensive Care Unit
Li, F., & Wimer, D. (2025) · Springer eBooks · doi:10.1007/978-3-031-77335-8_50 · Cited by 3
Reddi, B. A. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-43683-4_17 · Cited by 4
Endocrine interventions in the intensive care unit
Téblick, A., Langouche, L., & den Berghe, G. V. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819973-2.00028-9 · Cited by 4
Hypoglycemia and Hyperglycemia in Critically Ill Cancer Patients
Oğuz, S. H., Ünlütürk, U., Laçin, Ş., Gürlek, A., & Yalçın, Ş. (2019) · Springer eBooks · doi:10.1007/978-3-319-74588-6_89 · Cited by 3
Vasopressin in septic shock: what we know and where to next?
Young, P. J., Delaney, A. P., & Venkatesh, B. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05642-w · Cited by 3
Møller, M. H., Shankar‐Hari, M., & Alhazzani, W. A. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202005-1984ed · Cited by 3
Hydrocortisone in septic shock: is it worth it?
Young, P. J. (2020) · Critical Care and Resuscitation · doi:10.1016/s1441-2772(23)00385-x · Cited by 3
REMAP-CAP corticosteroids: yet, another swing of the pendulum?
Pirracchio, R., & Sprung, C. L. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-07957-3 · Cited by 3
Acute management of sepsis beyond 24 hours
Premachandra, A., & Heming, N. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1787991 · Cited by 2
Interpreting Clinical Trial Results
Kearney, C. M., Barlow, B., Pang, B., & Bosch, N. A. (2024) · CHEST Critical Care · doi:10.1016/j.chstcc.2024.100097 · Cited by 2
Haddad, G., Maslove, D. M., Mbuagbaw, L. C. E., Belley‐Côté, E. P., & Rochwerg, B. N. (2025) · Critical Care Explorations · doi:10.1097/cce.0000000000001210 · Cited by 3
Deng, Y., Wang, S., Zhou, S., Zhao, W., Wang, A., & Gao, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1663974 · Cited by 3
Ruyuan, L., Zhangshun, S., Li, H., & Jianling, S. (2025) · BMC Anesthesiology · doi:10.1186/s12871-025-03388-1 · Cited by 3
“Evaluated domains include: [1] randomization process [2], deviations from intended interventions [3], missing outcome data [4], outcome measurement, and [5] selection of the reported result.”
InfluentialChang, W.-H., Hu, T.-Y., & Kuo, L. (2026) · Diagnostics · doi:10.3390/diagnostics16010173 · Cited by 2
“…supportive strategies, including intravenous fluid strategies [30], choice of resuscitation targets (e.g., peripheral perfusion-based approaches versus lactate-driven strategies) [31], corticosteroid regimens [32,33], and vitamin C–based interventions with mixed findings across studies [34–36].”
Frapard, T., Gendreau, S., Kasbi, A., Meyer, A., Razazi, K., de Prost, N., Lavillegrand, J., & Dessap, A. M. (2026) · Annals of Intensive Care · doi:10.1016/j.aicoj.2026.100027 · Cited by 2
Zhang, Y., Wu, Y., Gao, H., Liu, Q., Lv, M., Wu, H., Liu, L., & Li, N. (2026) · Journal of Hospital Infection · doi:10.1016/j.jhin.2026.05.016 · Cited by 2
Managing sepsis in the era of precision medicine: a narrative review
Yong, H. J., Kim, S., & Kim, D. (2026) · Acute and Critical Care · doi:10.4266/acc.000884 · Cited by 2
“In contrast, the Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHS) trial demonstrated a sig‑ nificant reduction in mortality with hydrocortisone plus flud‑ rocortisone compared with placebo (43.0% vs. 49.1%, P=0.03) [54].”
InfluentialSung, J. J., Digholkar, G., & Pearson, R. M. (2026) · Small · doi:10.1002/smll.74914 · Cited by 2
“However, their clinical benefit remains inconsistent due to systemic toxicity, non-specific immunosuppression, increased infection risk, and variable efficacy [ 9, 10 ].”
Cost Analysis of Adjunctive Hydrocortisone Therapy for Septic Shock: U.S. Payer Perspective
Oh, M., Patanwala, A. E., Alkhatib, N. S., Almutairi, A. R., Abraham, I. L., & Erstad, B. L. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004501 · Cited by 2
“An editorial accompanying the publications of the ADRENAL and APROCCHSS trials stated that it was unlikely that further large-scale studies would be conducted that might guide clinicians’ decision-making on the use of hydrocortisone in patients with septic shock given that bedside estimation of 90-day mortality is not…”
InfluentialSuárez-de-la-Rica, A., Croes, B., Ciudad, L., Vallejo, I., Mújica, J., Díaz‐Almirón, M., & Maseda, E. (2022) · Revista Española de Quimioterapia · doi:10.37201/req/107.2022 · Cited by 3
“The use of corticosteroids has been shown to reverse septic shock [18,19], but only in one trial it was possible to control hydrocortisone administration [15].”
BackgroundBloos, F. (2023) · AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie · doi:10.1055/a-1813-2319 · Cited by 2
“Insbesondere die letzte Funktion dürfte dafür verantwortlich sein, dass Hydrokortison zu einem schnelleren Vasopressor-Weaning führt [18, 19].”
BackgroundInfluentialJochheim, L. S., Jochheim, D., Habenicht, L., Herner, A., Ulrich, J. D., Wiessner, J. R., Heilmaier, M., Rasch, S., Schmid, R. M., Lahmer, T., et al. (2023) · Journal of Intensive Care Medicine · doi:10.1177/08850666231160664 · Cited by 2
Adrenal Dysfunction Caused by a Critical Condition During Extracorporeal Membrane Oxygenation
Altshuler, N. Е., Губарев, К. К., Kutsy, M. B., & Popugayev, K. A. (2023) · Russian Sklifosovsky Journal Emergency Medical Care · doi:10.23934/2223-9022-2023-12-1-66-77 · Cited by 2
Luo, M.-H., Chen, J., Luo, J., Li, J.-K., Zhang, Y., Xu, X., Su, Y., Wang, C., Lai, H., Sun, Y., et al. (2023) · Perfusion · doi:10.1177/02676591231205124 · Cited by 2
Bayesian response adaptive randomization design with a composite endpoint of mortality and morbidity
Xu, Z., Ma, T., Tang, L., Talisa, V. B., & Chang, C. H. (2024) · Statistics in Medicine · doi:10.1002/sim.10014 · Cited by 2
Arnoux, A., Murris, J., Béchet, S., Jung, C., Auchabie, J., Dupeyrat, J., Anguel, N., Asfar, P., Badie, J. C., Carpentier, D., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2022-069430 · Cited by 2
Self-citationVine, J., Berlin, N., Moskowitz, A. L., Berg, K. M., Liu, X., Balaji, L., Donnino, M. W., & Grossestreuer, A. V. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107486 · Cited by 2
White, K. C., Chaba, A., Meyer, J., Ramanan, M., Tabah, A., Attokaran, A. G., Kumar, A., McCullough, J., Shekar, K., Garrett, P., et al. (2024) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2024.101435 · Cited by 4
Vasoaktive Substanzen im septischen Schock – individualisierte Strategien
Lehner, G. F., Mayerhöfer, T., Perschinka, F., Benda, B., & Joannidis, M. (2025) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-025-01272-x · Cited by 3
Lu, L.-L., Cao, Y.-L., Lu, Z.-C., Wu, H., Hu, S., Ye, B.-Q., He, J., Di, L., Chen, X., & Liu, Z. (2025) · Metabolites · doi:10.3390/metabo15050290 · Cited by 2
“However, antibiotics can lead to antimicrobial resistance and organ damage [4], whereas glucocorticoid anti-inflammatory drugs are often associated with gastrointestinal bleeding, metabolic disorders, and an increased risk of cardiovascular complications [5].”
Glucocorticoid Treatment in Community-Acquired Pneumonia
Dequin, P. F., & Confalonieri, M. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2704-6851 · Cited by 2
Endocrine and Electrolyte Disorders
Inglis, P., Moretti, E. W., & Funk, D. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-56724-4.00040-x · Cited by 2
Chausse, J., Malekele, L., & Paruk, F. (2018) · Southern African Journal of Critical Care · doi:10.7196/sajcc.2018.v34i1.361 · Cited by 2
Evidenzbasierte, interdisziplinäre Behandlung der abdominellen Sepsis
Schmoch, T., Al‐Saeedi, M., Hecker, A., Richter, D., Brenner, T., Hackert, T., & Weigand, M. A. (2019) · Der Chirurg · doi:10.1007/s00104-019-0795-6 · Cited by 2
Intensivmedizinische Studien aus 2017/2018
Reuß, C. J., Bernhard, M. H., Beynon, C., Hecker, A., Jungk, C., Nußhag, C., Weigand, M. A., Michalski, D., & Brenner, T. (2018) · Der Anaesthesist · doi:10.1007/s00101-018-0474-x · Cited by 3
Roquilly, A., & Asehnoune, K. (2019) · Anesthésie & Réanimation · doi:10.1016/j.anrea.2019.02.004 · Cited by 2
“Lorsque l’hydrocortisone est associée à un minéralocorticoïde (fludrocortisone) et administrée à des patients en choc septique sévère (mortalité en réanimation des groupes contrôles > 40%), une diminution de la mortalité a été constamment observée [36,37].”
BackgroundSelf-citationAdjunctive Therapies in the Management of Septic Shock
Parikh, R., Belok, S. H., Swamy, L., & Reardon, C. C. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1991rr · Cited by 2
Diagnosis and Management of Adrenal Insufficiency in Hospitalized Patients
Reddy, P. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001064 · Cited by 2
Akutes pulmorenales Syndrom auf der Intensivstation
Enghard, P., Erley, C. M. M., & Schreiber, A. (2019) · Der Nephrologe · doi:10.1007/s11560-019-00373-x · Cited by 2
The role of steroids in severe CAP
Nora, D., Nedel, W. L., Lisboa, T. C., Salluh, J. I., & Póvoa, P. M. S. R. (2020) · Hospital Practice · doi:10.1080/21548331.2020.1720215 · Cited by 2
“[114] randomized 1241 patients to hydrocortisone-plus-fludrocortisone therapy and placebo and found significantly lower 90-day-all-cause mortality among patients who received steroids.”
BackgroundVasopressor Dosing in Septic Shock Clinical Trials: A Systematic Review and Ecologic Study
Teja, B. J., Bosch, N. A., Walkey, A. J., Pinto, R. L., & Wunsch, H. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201908-599rl · Cited by 2
Niehaus, M. T., & Baldisseri, M. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-26710-0_102 · Cited by 2
Yehya, N. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.0689 · Cited by 2
24th International Symposium on Infections in the Critically Ill Patient
Artigas, A., Carlet, J. M., Garnacho, J., Niederman, M. S., & Torres, A. (2019) · Medical Sciences · doi:10.3390/medsci7020023 · Cited by 3
Pfeiffer, S., & Wong, H. R. (2021) · Springer eBooks · doi:10.1007/978-3-030-53363-2_17 · Cited by 2
Shock: causes, assessment and investigation
Dockrell, L., & Gantner, D. C. (2023) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2022.12.010 · Cited by 2
Venkatesh, B., & Cohen, J. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00470-8 · Cited by 2
Arab, O. A., Ly, A., Amrouche, I., Andrei, S., & Mongardon, N. (2019) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2019.06.003 · Cited by 2
Vasopressor use in septic shock: separating evidence, practice, and future directions
Fage, N., Chew, M. S., & Asfar, P. (2026) · Intensive Care Medicine · doi:10.1007/s00134-026-08337-1 · Cited by 2
Hydrocortisone plus fludrocortisone: Taichi of risk hedge for improving adults with septic shock
Chen, W., Wang, Y., & Zhong, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.18 · Cited by 1
“(1) in which the authors reported that hydrocortisone plus fludrocortisone therapy significantly improved 90-day all-cause mortality in patients with septic shock compared with placebo.”
BackgroundManejo da lesão renal aguda: uma revisão narrativa
Silva, J. M. M., Castro, C. M. C. D., Castilho, C. P. M., Melo, E. R., Carneiro, G. V., Faria, M. C. S., Rezende, P. D. S., Guirelle, Y. D. S., & Nascimento, T. R. M. (2021) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e7072.2021 · Cited by 1
Revisiting Old Friends: Adjunctive Therapies in Acute Respiratory Distress Syndrome
Gao, C. A., Mylvaganam, R. J., Poor, T. A., & Walter, J. M. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202009-3722rr · Cited by 1
Zhao, Q., Xiao, J., & Liu, H. (2022) · Emergency and Critical Care Medicine · doi:10.1097/ec9.0000000000000036 · Cited by 1
Clinical Management of Endotoxemia: Corticosteroids
Boscolo, A., Sella, N., Pettenuzzo, T., & Navalesi, P. (2023) · Springer eBooks · doi:10.1007/978-3-031-18591-5_8 · Cited by 1
Uso temprano de hidrocortisona para la disminución de mortalidad en pacientes con choque séptico
Ruiz, P. M., González, P. N., Zárate, C. R., Serrano, R. C., Díaz, B. A. M., & Sánchez, J. S. A. (2024) · Medicina Crítica · doi:10.35366/118214 · Cited by 1
Jiradechpitak, U., Tangsuwanaruk, T., Sitthiprawiat, P., & Wittayachamnankul, B. (2025) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2025.02.002 · Cited by 1
Neumann, C., Leitner, M., Bloos, F., Lange, D., Bogatsch, H., Annane, D., Fleuriet, J., Briegel, J., Bauer, M. W., SepNet Critical Care Trials Group, et al. (2025) · Infection · doi:10.1007/s15010-025-02569-x · Cited by 1
“The administration of corticosteroids is one of the few immunomodulatory treatments for selected patients with septic shock [7] despite controversial results [8–13], side effects, and corticosteroid resistance [14].”
Self-citationAlMubayedh, H. O., Almehizia, R., Salam, A., Alghunaim, R., Mohammed, O., Alrbiaan, A., & Al‐Qadheeb, N. S. (2025) · Critical Care Explorations · doi:10.1097/cce.0000000000001290 · Cited by 1
Emerging Paradigms in Sepsis Management: Critical Insights from Contemporary Clinical Trials
Sasidharan, S., & Dhillon, H. S. (2025) · APIK Journal of Internal Medicine · doi:10.4103/ajim.ajim_32_25 · Cited by 1
Comparative Effectiveness of Less vs. More Frequent Hydrocortisone Dosing in Septic Shock
Hao, A., Wu, T. D., Collins, K., Guffey, D., Kessinger, R., Vallabh, M., & Omranian, A. (2025) · Critical Care Explorations · doi:10.1097/cce.0000000000001316 · Cited by 1
Yang, D., Jiang, C., & Xiao, Z. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108425 · Cited by 1
Cavaillon, J., & Carlet, J. M. (2025) · EXCLI journal · doi:10.17179/excli2025-8514 · Cited by 3
Cripe, L., Malach, L., Bartholomew, R., Schachter, A. E., Gwin, J. C., Dong, C. T., Jones, C. E., Byerly, S. E., Gandhi, D., Howley, I., et al. (2025) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2025.116680 · Cited by 1
[Translated article] Sepsis and septic shock
Bastida, C., Lugea, A. E., Fernández-Polo, A., Moreno, F. B., Cerezuela, M. M., Chiva, E. D., García, T. B., García, M. Á. A., González, I., Albanell‐Fernández, M., et al. (2025) · Farmacia Hospitalaria · doi:10.1016/j.farma.2025.10.005 · Cited by 2
Chang, W.-H., Hu, T.-Y., & Kuo, L. (2025) · Diseases · doi:10.3390/diseases13120382 · Cited by 1
“This precluded any mechanistic inference regarding the efficacy of source control or CytoSorb in infection eradication [33].”
Current and emerging therapeutic options for refractory septic shock: A systematic review
Nácul, F. E., Bezerra, M. B., Gomes, B. C., Hohmann, F. B., Treml, R. E., Caldonazo, T. M. M., da Silva, A. A., Passos, R. D. H., de Oliveira, N. E., Bedretchuk, G. P., et al. (2025) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v14.i4.111164 · Cited by 1
Evaluation of Stress-Dose Steroid Weaning Strategies in Patients Following Septic Shock
Denninger, J. M., Toler, J. A., Skovran, S., & Westlake, E. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251385523 · Cited by 1
Refractory septic shock: our updated pragmatic approach
Palmesino, F., Woodman-Bailey, A., Hanks, F., Khoo, S., Ostermann, M., Ioannou, N., Meadows, C. I. S., & Wyncoll, D. L. A. (2026) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-025-00336-w · Cited by 1
“There remains uncertainty over the role of fludrocorti-sone in improving shock outcomes with conflicting randomised controlled trials [12, 13].”
Shock: causes, assessment and investigation
Tan, L. T. N., & Dockrell, L. (2026) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2025.12.005 · Cited by 1
Chalermwutanon, A., Saejaow, S., & Vattanavanit, V. (2026) · Acute and Critical Care · doi:10.4266/acc.000125 · Cited by 1
“Patients in our study appeared to be more severely affected than those in previous studies, as indicated by a mortality rate of 56.2% in patients with septic shock, compared to ≤50% in two recent major randomized trials of steroid use in septic shock [13,21].”
InfluentialA novel CD112-derived peptide targeting gut-primed neutrophils to attenuate deadly hepatic injury
Kato, T., Murao, A., Jha, A., Ma, G., Aziz, M., & Wang, P. (2026) · Molecular Medicine · doi:10.1186/s10020-026-01426-3 · Cited by 1
“Although systemic corticosteroids are commonly used to blunt widespread inflammation and protect multiple organs (Cain and Cidlowski 2017; Annane et al. 2018; Venkatesh et al. 2018), their broad inhibition of cytokine pathways and suppression of neutrophil function can increase susceptibility to…”
Update der S3-Leitlinie Sepsis 2025 – was ist neu?
Rusev, S., Bergmann, L., Unterberg, M., Adamzik, M., & Rahmel, T. (2026) · AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie · doi:10.1055/a-2697-1050 · Cited by 1
Harb, H. (2026) · Information · doi:10.3390/info17050430 · Cited by 1
Glucocorticoids in pregnancy: a master-switch for fetal maturation
Tan, Y., Stark, M. J., Clifton, V. L., Wiese, M. D., Morrison, J. L., & Gatford, K. L. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag015 · Cited by 1
ARDS and corticosteroids: beyond COVID-19
Esperatti, M., Olmos, M., & Fuentes, N. A. (2026) · Pneumonia · doi:10.1186/s41479-026-00200-7 · Cited by 1
“In trials dem‑ onstrating benefit, treatment was most commonly initi‑ ated within the first 24–48 hours after ARDS onset [17, 26, 31, 51], whereas delayed administration—particularly beyond day 14—appears not only to lack benefit but may cause harm [41].”
Nuclear receptors shape sepsis pathophysiology
Jelinek, M., Bosscher, K. D., Libert, C., & Vandewalle, J. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag017 · Cited by 1
Current and future strategies aiming at reducing catecholamine exposure in septic shock
Dubech, A., Picod, A., Pierre, A., Préau, S., Favory, R., & Garcia, B. (2026) · Critical Care · doi:10.1186/s13054-026-06109-3 · Cited by 1
Ahn, S., Ahn, C., Hwang, S. Y., Kim, S.-M., Park, J.-H., Kim, W. Y., Park, S.-J., Choi, S.-H., Kwon, W. Y., Kong, T., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-56521-6 · Cited by 2
“Current recommendations largely reflect the inclusion criteria of major ICU-based randomized controlled trials, which defined an ongoing vasopressor requirement as a norepinephrine or epinephrine dose ≥ 0.25 µg/kg/min for at least 4 h to maintain target mean arterial pressure 2,3,10,11,18 .”
InfluentialManagement Algorithm for Vasoplegic Shock After Cardiac Surgery: An Interdisciplinary Collaboration
Chatterjee, S., Ortoleva, J. P., Arora, R. C., Dalton, K., Engelman, D. T., Girardi, L. N., Grant, M. C., Miles, T. J., Moon, M. R., Suero, O. R., et al. (2026) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2026.06.013 · Cited by 1
Melo, P., Wendel‐Garcia, P. D., Léone, M., Khanna, A. K., Morales, S., Ospina-Tascón, G. A., Castro, R., Glenn Hernández, P., & Kattan, E. (2026) · Critical Care · doi:10.1186/s13054-026-06197-1 · Cited by 1
“…shock duration without mortality benefits [63], whereas the more unstable APROCCHSS (Activated Protein C and Corticosteroids for Human Septic Shock) cohort had reduced 90-day mortality with hydrocortisone plus fludrocortisone [64], with supportive signals in pneumonia-related septic shock [65].”
When to initiate immunomodulatory therapy in sepsis
Wen, Y., & Huang, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1898450 · Cited by 1
Sepsis as CNS-governed metabolic triage
Yurtsever, B., & Demirkol, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1842915 · Cited by 1
Cardiac Complications in Neurocritical Care Patients
Kim, J. A., & Izzy, S. (2020) · Current clinical neurology · doi:10.1007/978-3-030-36548-6_4 · Cited by 1
Scoring systems for sepsis: which purposes can they serve?
Brun‐Buisson, C. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.07.002 · Cited by 1
Self-citationSepsis-Update: evidenzbasierte Therapie
Märtin, L., Bickenbach, J., & Marx, G. (2019) · AINS - Anästhesiologie · Intensivmedizin · Notfallmedizin · Schmerztherapie · doi:10.1055/a-0625-5521 · Cited by 1
“Die ebenfalls erst kürzlich abgeschlossene APROCCHSSStudie (APROCCHSS = „Hydrocortisone plus Fludrocortisone for Adults with Septic Shock“) untersuchte an 1241 Patienten den Einfluss von Hydrokortison (200mg/ d) in Kombination mit Fludrokortison (50 μg/d) auf die 90-Tage-Sterblichkeit bei Patienten mit septischem Scho…”
BackgroundSepsis and Septic Shock: A Review of Definitions, Pathogenesis, and Treatment
Butler, T., & Levin, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-17148-3_22 · Cited by 2
High versus low blood pressure targets for cardiac surgery with cardiopulmonary bypass
Kotani, Y., Kataoka, Y., Izawa, J., Fujioka, S., Yoshida, T., Kumasawa, J., & Kwong, J. S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013494 · Cited by 1
The critical care literature 2018
Winters, M. E., Hu, K. M., Martinez, J. P., Mallemat, H. A., & Brady, W. J. (2019) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2019.11.032 · Cited by 1
Critical Illness Related Corticosteroid Insufficiency (CIRCI)
Khosla, A. J., & Ahasic, A. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-26710-0_55 · Cited by 1
Blood glucose and outcomes in critically ill children in Brazilian Amazon: an observational study
de Farias, E. C. F., de Carvalho, P. B., Júnior, M. J. C. P., Dias, L. G., Alves, M. C. B., Alves, S. F. L., da Silva, E. R., Dias, B. T. P., dos Reis, J. H. S., Cunha, K. D. C., et al. (2021) · Research Society and Development · doi:10.33448/rsd-v10i2.12813 · Cited by 1
“…despite being widely used as an adjuvant to reduce state duration, mortality, as well as to prevent its transition to multiple organ dysfunction (Annane et al., 2018; Darmaros et al., 2016), its benefits may depend on variables such as initial risk mortality or may be absent, as demonstrated by…”
BackgroundInfective endocarditis, is there a goal beyond antibiotics and surgery?
Guery, B. P., & Papadimitriou‐Olivgeris, M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.10.033 · Cited by 1
Update der Surviving-Sepsis-Campaign-Leitlinie 2021 – Was ist neu?
Briegel, J., & Möhnle, P. (2022) · Der Anaesthesist · doi:10.1007/s00101-022-01087-x · Cited by 1
The Endocrine Response to Stress
Henley, D., Upton, T. J., & Lightman, S. L. (2022) · doi:10.1093/med/9780198870197.003.0203 · Cited by 1
Janus face of sepsis: a viewpoint
Bauer, M. W., & Wetzker, R. (2022) · Exploration of Immunology · doi:10.37349/ei.2022.00051 · Cited by 1
“Whereas a recent French study reported outcome benefit from a combination of hydrocortisone plus oral fludrocortisone [32], the pan-European Corticosteroid Therapy of Septic Shock (CORTICUS) trial and the 5-country ADRENAL trial found no survival effect from hydrocortisone alone [33, 34].”
BackgroundContou, D., & de Prost, N. (2022) · Médecine Intensive Réanimation · doi:10.37051/mir-00097 · Cited by 3
Bartlett, R. H., Carlet, J. M., Cook, D., Gattinoni, L., Harvey, M. A., Jacobi, J., Parker, M. M., Sprung, C. L., Suter, P. M., Thompson, A., et al. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005728 · Cited by 2
Pérez, G. F. F., Pulgarín, G. A. Z., & Cevallos, J. F. N. (2023) · Brazilian Journal of Health Review · doi:10.34119/bjhrv6n1-341 · Cited by 2
Chinaeke, E. E., Yunusa, I. U., Love, B. L., Magagnoli, J., & Reeder, C. E. (2023) · American Journal of Pharmacotherapy and Pharmaceutical Sciences · doi:10.25259/ajpps_2023_005 · Cited by 1
Deng, Y.-Z., Luo, M.-H., Luo, J., Li, J.-K., Chen, J., Zhang, Y., Hou, J., Su, Y., Tu, G.-W., & Luo, Z. (2023) · BMC Anesthesiology · doi:10.1186/s12871-023-02124-x · Cited by 1
“With regarding to vascular paralysis induced hypotension, recent clinical studies such as the APROCCHSS trial, have noted that the use of low doses of GC improves 90-day mortality and increases the likelihood of shock reversal in intractable shock [11].”
BackgroundBouras, M., Clément, A., Schirr-Bonnans, S., Mauduit, N., Péré, M., Roquilly, A., Riche, V.-P., & Asehnoune, K. (2023) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2023.111218 · Cited by 1
Self-citation
Metadata
- Authors
- Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J.-P., Siami, S., Cariou, A., Forceville, X., Schwebel, C., Martin, C., Timsit, J.-F., Misset, B., Ali Benali, M., Colin, G., Souweine, B., Asehnoune, K., Mercier, E., Chimot, L., Charpentier, C., François, B., Boulain, T., Petitpas, F., Constantin, J.-M., Dhonneur, G., Baudin, F., Combes, A., Bohé, J., Loriferne, J.-F., Amathieu, R., Cook, F., Slama, M., Leroy, O., Capellier, G., Dargent, A., Hissem, T., Maxime, V., & Bellissant, E.
- Affiliations
- Inserm (FR)
- From Service de Médecine Intensive et Réanimation, Hôpital Raymond Poincaré, Garches (D.A., V.M.), Laboratory of Infection and Inflammation Unité 1173, University of Versailles Saint-Quentin-en-Yvelines, INSERM, Montigny-le-Bretonneux (D.A.), Service de Pharmacologie Clinique–Centre d’Investigation Clinique (CIC) INSERM 1414, Centre Hospitalier Universitaire (CHU) de Rennes–Université de Rennes 1, Hôpital Pontchaillou, Rennes (A.R., E.B.), Service de Réanimation Médicale (C.B.-B.) and Service...
- ORCID
- Annane, Djillali
- Renault, Alain
- Quenot, Jean-Pierre
- Siami, Shidasp
- Cariou, Alain
- Forceville, Xavier
- Schwebel, Carole
- Misset, Benoît
- Souweine, Bertrand
- Asehnoune, Karim
- François, Bruno
- Boulain, Thierry
- Constantin, Jean-Michel
- Combes, Alain
- Bohé, Julien
- Amathieu, Roland
- Cook, Fabrice
- Slama, Michel
- Capellier, Gilles
- Dargent, Auguste
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 809-818
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2794125559
- Cited by
- 939
- References
- 22
- Citations by year
- 2026: 107 · 2025: 104 · 2024: 97 · 2023: 115 · 2022: 101 · 2021: 98 · 2020: 121 · 2019: 123 · 2018: 70
- FWCI
- 80.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Funders
- Ministère des Affaires Sociales et de la Santé (Programme Hospitalier de Recherche Clinique / P 07)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- cortisol, fludrocortisone, drotrecogin alfa (activated), corticosteroid therapy, host response to infection, 90-day mortality, vasopressor-free days, organ failure, mechanical ventilation, intensive care unit discharge, sepsis treatment
- MeSH terms
- Simplified Acute Physiology Score, Aged, Anti-Inflammatory Agents, Cause of Death, Combined Modality Therapy, Double-Blind Method, Drug Therapy, Combination, Female, Fludrocortisone, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Analysis, Treatment Outcome, Renal Replacement Therapy, Organ Dysfunction Scores
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.